Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency
To the Editor: Tumor necrosis factor (TNF)-like receptors are members of a superfamily of proteins involved in regulating maturation and survival of lymphocytes. One of these receptors, TACI (transmembrane activator and CAML interactor; encoded by TNFRSF13B), binds two ligands, BAFF and APRIL. Deletion of Tnfrsf13b in mice results in an impaired response to thymus-independent antigens 1 and virtually abolishes APRIL-induced switching to IgA, IgE and IgG1 (ref. 2) . Conversely, lack of APRIL, owing to a targeted inactivation of Tnfsf13 in mice, results in an impaired ability to switch to IgA production 3 .
Recently, two studies have reported that sequence variants in TNFRSF13B are associated with primary immunodeficiency diseases in humans 4, 5 . Specifically, common variable immunodeficiency (CVID) was found to be associated with homozygosity for several coding variants (S144X, C104R and A181E) 4 ; in addition, heterozygous coding variants (C104R, A181E, S194X, R202H and ins204A) were identified in several individuals with CVID 4, 5 . Furthermore, Castigli et al. 5 showed a strict correlation between the presence of heterozygous coding variants (C104R, A181E and R202H) and CVID and selective IgA deficiency (IgAD) in members of their multicase families, suggesting a causal relationship. In our study 4 , one of the siblings of a CVID proband, who is heterozygous for the A181E variant, suffered from IgAD. However, her mother, who is also heterozygous for the A181E variant, had normal immunoglobulin levels, suggesting incomplete penetrance 4 .
Here we report that a significant proportion of the normal population carries heterozygous coding variants in TNFRSF13B ( Table 1 ). Using a SNP-based assay 4, 6 (for primer sequences, see Supplementary Table 2 online), we did not find an overrepresentation of C104R, A181E or ins204A in our IgAD case series ( Table 1  and Supplementary Table 1) , nor did we identify any individuals who were homozygous or compound heterozygous for any of the coding variants. However, we found two individuals with IgAD who were heterozygous for the R202H variant, whereas we did not find any R202H heterozygotes among the Swedish controls (Table 1) . Subsequently, we investigated the family members of the ten probands with IgAD who carried the C104R, A181E or R202H variants, five of whom belonged to multicase families. However, IgA deficiency did not cosegregate with the TACI coding variants (see families 1, 5, 7 and 10 in Supplementary  Table 3 and Supplementary Fig. 1 online) , and the transmission disequilibrium test (calculated using TRANSMIT) showed no linkage or association.
Thus, our sequence analysis of TNFRSF13B in a large number of cases and controls provides supporting evidence that heterozygous C104R, A181E and ins204A sequence variants in TNFRSF13B constitute risk factors for the development of CVID. However, our data suggest that these variants have only minor roles, if any, in the development of selective IgAD. We are currently examining the functional effects of the heterozygous TACI variants to better understand the mechanism by which these variants contribute to the development of CVID. d Homozygous sequence variants were excluded from the calculation.
e One 'control' heterozygous for the A181E allele was found to be hypogammaglobulinemic (serum level of IgG = 3.7 g/l).
The institutional review boards at the Karolinska Institute approved this study, and informed consent was obtained from all patients.

To the Editor:
Two studies, including one by our group, have recently reported that coding variants in TNFRSF13B, which encodes TACI (transmembrane activator and CAML interactor), are associated with primary immunodeficiencies in humans 1,2 . In our original study 1 , we reported heterozygous TNFRSF13B coding variants in 4 of 19 individuals with common variable immunodeficiency (CVID). Since then, we have collected sequencing data on 106 individuals with CVID and 62 controls. The genotype frequencies for the coding variants we observed are given in Table 1 .
We found a significant association between CVID and the heterozygous coding variants C104R (5/212 versus 0/124; P = 0.030 by χ 2 test) and A181E (4/212 versus 0/124; P = 0.052). We also observed five heterozygous variants (L69fsX11, Gly76fsX3, R72H, L171R and R202H) in individuals with CVID but not in controls, but the differences were not statistically significant. One of these variants, R72H, has been previously reported in healthy controls 2 . Finally, we observed six variants in both affected individuals and controls. Two of these result in amino acid substitutions (V220A and P251L) and have been described previously [1] [2] [3] . These additional data support our initial conclusion that TACI coding variants, especially C104R and A181E, are associated with CVID. Nevertheless, it is important to note that the A181E variant, at least, has been found in healthy individuals, albeit at a frequency significantly lower (P < 0.001) than in individuals with CVID 2 . This, together with the clinical heterogeneity that we originally noted in family members who carry the same TACI variants as the probands, suggests that other genes may exert important influences on the phenotype associated with TACI coding variants, as in many other genetically inherited primary immunodeficiencies. It is also possible that some of the 'normal' individuals who carry these TACI coding variants might eventually develop CVID later in life, as the age at onset Sequencing of all five exons of TNFRSF13B was performed on genomic DNA of all subjects as previously described 1 . Informed consent was obtained from all subjects, and the study was approved by the Ethics Committee/Institutional Review Board of Children's Hospital, Boston.
